Radiation Oncology Unit, Pisa University Hospital, Via Roma 67, 56123, Pisa, Italy.
Department of Clinical and Experimental Medicine, University of Pisa, I-56126, Pisa, Italy.
Invest New Drugs. 2021 Aug;39(4):1159-1165. doi: 10.1007/s10637-021-01075-9. Epub 2021 Feb 8.
This study reports the results of a monocentric prospective analysis conducted with the aim of evaluating the impact of XRCC1 rs25487, XRCC3 rs861539, XRCC3 rs1799794, RAD51 rs1801320 and GSTP-1 rs1695 single nucleotide polymorphisms (SNP) on patients with high-grade glioma treated with concomitant radio-chemotherapy. From October 2010 to August 2019, a total of 75 patients aged ≥18 years, with histological diagnosis of high-grade glioma, isocitrate dehydrogenase (IDH) 1/2 wild type and treated with radio-chemotherapy and sequential chemotherapy with temozolomide (TMZ) were prospectively recruited. The local ethic committee approved this study (Comitato Etico di Area Vasta Nord Ovest [CEAVNO]; protocol 3304/2011). After a median follow up of 25 months (range: 7-98 months), median progression-free survival (PFS) and overall survival (OS) were 11 months (CI95%: 8-14 months) and 18 months (CI95%: 15-21 months), respectively. In univariate and multivariate Cox regression analysis, a statistically significant association with PFS and OS was found with XRCC3 rs1799794 SNP. The study suggests that XRCC3 rs1799794 SNP can be associated with different PFS and OS in glioblastoma patients treated with radio-chemotherapy.
这项研究报告了一项单中心前瞻性分析的结果，该分析旨在评估 XRCC1 rs25487、XRCC3 rs861539、XRCC3 rs1799794、RAD51 rs1801320 和 GSTP-1 rs1695 单核苷酸多态性（SNP）对接受同期放化疗的高级别脑胶质瘤患者的影响。2010 年 10 月至 2019 年 8 月，共前瞻性招募了 75 名年龄≥18 岁、组织学诊断为高级别脑胶质瘤、异柠檬酸脱氢酶（IDH）1/2 野生型、接受放化疗和替莫唑胺（TMZ）序贯化疗的患者。当地伦理委员会批准了这项研究（Comitato Etico di Area Vasta Nord Ovest [CEAVNO]；方案 3304/2011）。中位随访 25 个月（范围：7-98 个月）后，中位无进展生存期（PFS）和总生存期（OS）分别为 11 个月（95%CI：8-14 个月）和 18 个月（95%CI：15-21 个月）。单因素和多因素 Cox 回归分析显示，XRCC3 rs1799794 SNP 与 PFS 和 OS 有统计学显著关联。该研究表明，XRCC3 rs1799794 SNP 可能与接受放化疗的胶质母细胞瘤患者的不同 PFS 和 OS 相关。
